# A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

> **NCT04655911** · — · TERMINATED · sponsor: **Abeona Therapeutics, Inc** · enrollment: 1 (actual)

## Conditions studied

- Mucopolysaccharidosis III-B

## Interventions

- **BIOLOGICAL:** ABO-101

## Key facts

- **NCT ID:** NCT04655911
- **Lead sponsor:** Abeona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-28
- **Primary completion:** 2022-04-07
- **Final completion:** 2022-04-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Abeona has decided to discontinue development activities for Product AB0-101 due to a lack of drug supply and for business reasons unrelated to the product safety profile and/or signs of efficacy
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655911, "A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04655911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*